Maravai LifeSciences Inc... (MRVI)
1.74
-0.03 (-1.69%)
At close: Apr 15, 2025, 3:59 PM
1.75
0.92%
After-hours: Apr 15, 2025, 07:56 PM EDT
Maravai LifeSciences Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biologics Safety Testing Segment Revenue | 15.25M | 18.16M | 15.32M | 15.64M | 15.65M | 17.57M | 15.42M | 16.38M | 17.48M | 20.64M | 15.93M | 16.63M | 18.21M | 52.95M |
| Biologics Safety Testing Segment Revenue Growth | -16.02% | +18.57% | -2.05% | -0.07% | -10.95% | +13.95% | -5.85% | -6.30% | -15.30% | +29.55% | -4.16% | -8.69% | -65.61% | n/a |
| Nucleic Acid Production Segment Revenue | 49.95M | 46.02M | 58.83M | 51.23M | 53.27M | 61.45M | 189.29M | 174.88M | 225.25M | 223.65M | 212.51M | 182.9M | 192.52M | 372.03M |
| Nucleic Acid Production Segment Revenue Growth | +8.54% | -21.77% | +14.83% | -3.82% | -13.32% | -67.54% | +8.24% | -22.36% | +0.71% | +5.24% | +16.19% | -5.00% | -48.25% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 |
|---|---|
| Asia Pacific Revenue | 97.44M |
| Asia Pacific Revenue Growth | n/a |
| Emea Revenue | 49.92M |
| Emea Revenue Growth | n/a |
| Latin And Central America Revenue | 527K |
| Latin And Central America Revenue Growth | n/a |
| North America Revenue | 141.06M |
| North America Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 39.09M | 40.56M | 31.2M | 33.63M | 38.86M | 35.38M | 38.67M | 37.2M | 30.8M | 28.06M | 33.2M | 25.58M | 25.19M | 24.09M | 23.24M | 41.62M | 20.51M | 15.99M | 16.13M | 15.78M |
| Selling, General, and Administrative Revenue Growth | -3.62% | +30.00% | -7.22% | -13.48% | +9.86% | -8.52% | +3.95% | +20.81% | +9.74% | -15.48% | +29.78% | +1.56% | +4.58% | +3.65% | -44.17% | +102.93% | +28.28% | -0.86% | +2.17% | n/a |
| Research and Development Revenue | 4.34M | 5.28M | 5.03M | 4.59M | 4.35M | 4.19M | 4.14M | 5.01M | 5.39M | 4.27M | 3.69M | 9.18M | 1.95M | 1.93M | 2.16M | 2.09M | 1.87M | 1.6M | 3.74M | 979K |
| Research and Development Revenue Growth | -17.79% | +5.01% | +9.53% | +5.68% | +3.65% | +1.18% | -17.28% | -7.01% | +26.09% | +15.67% | -59.77% | +370.97% | +0.93% | -10.72% | +3.44% | +11.99% | +16.75% | -57.26% | +282.43% | n/a |